The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Mind Medicine Inc shares valued at $78,139 were sold by Sullivan Mark on Jun 25 ’25. At $6.80 per share, Sullivan Mark sold 11,491 shares. The insider’s holdings dropped to 305,130 shares worth approximately $3.05 million following the completion of this transaction.
Also, Karlin Daniel sold 7,848 shares, netting a total of over 53,366 in proceeds. Following the sale of shares at $6.80 each, the insider now holds 438,329 shares.
Before that, Barrow Robert had sold 26,491 shares from its account. In a trade valued at $180,139, the Chief Executive Officer traded Mind Medicine Inc shares for $6.80 each. Upon closing the transaction, the insider’s holdings decreased to 26,491 shares, worth approximately $8.29 million.
Analysts at Evercore ISI started covering the stock with ‘”an Outperform”‘ outlook in a report released in late January. As of December 20, 2024, Chardan Capital Markets has initiated its “Buy” rating for MNMD.
Analyzing MNMD Stock Performance
On last trading session, Mind Medicine Inc [NASDAQ: MNMD] rose 1.01% to $9.99. The stock’s lowest price that day was $9.63, but it reached a high of $10.0196 in the same session. During the last five days, there has been a surge of approximately 9.90%. Over the course of the year, Mind Medicine Inc shares have jumped approximately 33.73%.
Is Mind Medicine Inc subject to short interest?
Stocks of Mind Medicine Inc saw a sharp rise in short interest on 2025-07-15 jumping by 0.16 million shares to 11.22 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 11.07 million shares. A jump of 1.41% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.97 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.97.
Which companies own the most shares of Mind Medicine Inc (MNMD)?
In terms of Mind Medicine Inc share price expectations, FactSet research, analysts set an average price target of 16 in the next 12 months, up nearly 61.78% from the previous closing price of $9.89. Analysts anticipate Mind Medicine Inc stock to reach 16 by 2025, with the lowest price target being 16. In spite of this, 2 analysts ranked Mind Medicine Inc stock as Buy at the end of 2025. On July 24, 2024, ROTH MKM assigned a price target of “a Buy” to the stock and initiated coverage with a $36.
